Download PDF
Pneumologie 2014; 68(07): 488-491
DOI: 10.1055/s-0034-1365487
Fallbericht
© Georg Thieme Verlag KG Stuttgart · New York

Schwere disseminierte Infektion durch Mycobacterium bovis BCG als Folge einer intravesikalen BCG-Therapie: Diagnostische Herausforderungen und therapeutische Optionen

Severe Disseminated Mycobacterium bovis BCG Infection as a Consequence of Intravesical BCG Therapy: Diagnostic Challenges and Therapeutic Options
P. Stais
Medizinische Klinik III, Krankenhaus Bethanien, Moers
,
K. Kambartel
Medizinische Klinik III, Krankenhaus Bethanien, Moers
,
A. Yildirim
Medizinische Klinik III, Krankenhaus Bethanien, Moers
,
T. Voshaar
Medizinische Klinik III, Krankenhaus Bethanien, Moers
› Author Affiliations
Further Information

Publication History

eingereicht16 December 2013

akzeptiert nach Revision18 March 2014

Publication Date:
13 May 2014 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Wir präsentieren den Fall eines 65-jährigen Patienten, der an einem oberflächlichen Harnblasenkarzinom leidet und infolge einer intravesikalen BCG-Therapie eine kritische systemische inflammatorische Reaktion aufgrund einer Disseminierung von Mycobacterium bovis BCG in Leber und Lunge erlitt. Neben der antituberkulotischen Therapie unter Beachtung einer Primärresistenz des M. bovis BCG gegenüber PZA diskutieren wir, basierend auf publizierten Fallberichten, die Möglichkeiten einer immunmodulierenden Therapie mit Steroiden [1].

Abstract

We present the case of a 65-year-old patient with superficial carcinoma of the bladder who developed systemic inflammatory reaction as a result of a severe disseminated infection with M. bovis BCG after intravesical instillation of BCG. Besides the recommended antituberculosis therapy, considering the resistance of M. bovis to PZA, we discuss here the option of using steroids in the therapeutic management of this patient.

 

  • Literatur

  • 1 Caramori G, Artioli D, Ferrara G et al. Severe pneumonia after intravesical BCG instillation in a patient with invasive bladder cancer: case report and literature review. Monaldi Arch Chest Dis 2013; 79: 44-48
    PubMedGoogle Scholar
  • 2 Uetsuki H, Hirama H, Matsuoka Y et al. A case with hepatitis and interstitial pneumonitis caused by intravesical bacillus Calmette-Guérin (BCG) instillation. Nihon Hinyokika Gakkai Zasshi 2011; 102: 691-695
    PubMedGoogle Scholar
  • 3 Sylvester RJ. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. Int J Urol 2011; 18: 113-120 [Epub 2010 Nov 22]
    CrossrefPubMedGoogle Scholar
  • 4 Askeland EJ, Newton MR, O'Donnell MA et al. Bladder Cancer Immunotherapy: BCG and Beyond. Adv Urol 2012; 181-987 [Epub 2012 Jun 20]
    PubMedGoogle Scholar
  • 5 Rodríguez F, Palou J, Martínez R et al. Practical guideline for the management of adverse events associated with BCG installations. Arch Esp Urol 2008; 61: 591-596
    PubMedGoogle Scholar
  • 6 Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006; 175: 2004-2010
    CrossrefPubMedGoogle Scholar
  • 7 Lamm DL. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 1992; 19: 565-572
    PubMedGoogle Scholar
  • 8 Schaberg T, Bauer T, Castell S et al. Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP). Pneumologie 2012; 66: 133-171
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Rival G, Garot D, Mercier E et al. Acute respiratory failure and septic shock induced by Mycobacterium bovis. A rare side effect of intravesical BCG therapy. Presse Med 2006; 35: 980-982
    CrossrefPubMedGoogle Scholar